What Is Dapiglutide?

1. What is dapiglutide and how does it work?

Dapiglutide is a single peptide that activates two receptors. The DREAM trial paper describes it as a 33-amino-acid peptide with a C18 acyl (fatty-acid) modification that extends its half-life to about five days, allowing once-weekly injection. It is roughly three times more selective for the GLP-1 receptor than for the GLP-2 receptor (Nielsen et al., EClinicalMedicine 2026).

GLP-1 (glucagon-like peptide-1) is the hormone mimicked by semaglutide and liraglutide. It reduces appetite, slows stomach emptying and boosts insulin release after meals.

GLP-2 comes from the same precursor protein as GLP-1 and is released by the same gut cells, but it does a different job. It makes the lining of the small intestine grow, increasing villus height and absorptive surface, which is why GLP-2 drugs such as teduglutide and glepaglutide are used or developed for short bowel syndrome. The DREAM authors note that GLP-2 could also reduce obesity-associated low-grade inflammation by tightening the gut barrier, although this “has not been thoroughly investigated” in obesity (Nielsen et al. 2026).

The DREAM paper also reports that, in laboratory tests, dapiglutide showed biased signaling at the GLP-1 receptor: prolonged cAMP activation with reduced recruitment of beta-arrestin, a protein that pulls receptors inside the cell. That design is shared with several newer incretin drugs. Whether it changes results in people has not been shown.

A clarification about “GLP-2”

Online, “GLP-2” is sometimes used loosely for dual agonists such as tirzepatide, which actually targets GLP-1 and GIP. The GLP-1 vs GLP-2 vs GLP-3 guide explains that slang. Dapiglutide is different: it genuinely activates the GLP-2 receptor.

2. Where did dapiglutide come from?

Zealand Pharma has a long history with GLP-2 peptides, including glepaglutide, which it took through Phase 3 trials in short bowel syndrome (NCT03690206). Dapiglutide’s first published studies were in mice with a surgically shortened bowel. In that model, it improved glucose tolerance, slowed intestinal transit, increased villus height and intestinal length, and reduced stool water losses, helping the animals recover body weight (Reiner et al., JPEN 2022). A follow-up study found it tightened the barrier between cells in the jejunum, the middle part of the small intestine (Reiner et al., Ann N Y Acad Sci 2022).

Zealand then took the drug into healthy volunteers and, in June 2022, announced it would move into obesity, with an investigator-initiated Phase 2 trial planned to start by early 2023 (Zealand, June 2022). Unlike its partnered programs, Zealand kept full ownership of dapiglutide (BioSpace, November 2025).

3. What did the clinical trials show?

Dapiglutide went through four trials in people. The doses rose sharply over time, and so did the weight loss.

Sources: Zealand nine-month 2025 report; Nielsen et al. 2026. None of these trials added diet or exercise programs. Doses identify research arms, not prescribing guidance.

Phase 1 in healthy volunteers

Zealand’s first single- and multiple-dose studies (NCT03994549 and NCT04612517) established the weekly schedule. Over four weeks, dapiglutide produced dose-dependent weight loss of up to 4.3%, delayed gastric emptying, and lowered glucose and insulin. The mean half-life was 123–129 hours across the four dose cohorts, and no participant developed anti-drug antibodies. There were no serious or severe adverse events and no withdrawals (Zealand, June 2022).

DREAM: the only peer-reviewed obesity trial

DREAM was run by researchers at Gentofte Hospital in Copenhagen, with an unrestricted grant from Zealand. It randomized 54 adults with a BMI of at least 30 (63% women, mean weight 101.3 kg, mean BMI 35.2) to weekly dapiglutide 4 mg, 6 mg or placebo for 12 weeks, between April 2023 and April 2024 (Nielsen et al. 2026).

The primary result was negative. Compared with placebo, 6 mg changed body weight by -2.1 percentage points (95% CI -4.3 to 0.2; p = 0.076), which did not reach statistical significance. Within-group weight change was -4.3% on 6 mg, -2.9% on 4 mg and -2.2% on placebo. The 6 mg group did show nominally larger falls in waist circumference (5.3 cm, versus a 0.4 cm rise on placebo), BMI and HbA1c than placebo, though only the HbA1c difference remained significant after correcting for multiple comparisons (Nielsen et al. 2026).

The authors concluded that 4 and 6 mg sit at the low end of the dose-response curve, and that the short duration, small size and lack of a lifestyle program also limited the result. They called for higher doses in larger, longer trials.

Phase 1b: higher doses, much more weight loss

Zealand’s Phase 1b trial (NCT06000891) tested those higher doses. In Part 1, 54 adults with a BMI of 27 to 39.9 (about 85% male, median BMI 30) received 13 weekly doses, titrated every second week to 7.5, 10 or 13 mg. Placebo-corrected weight loss reached up to 8.3%: up to 6.2% loss on dapiglutide, while the placebo group gained 2.1% (Zealand, September 2024).

In Part 2, 30 participants were randomized 2:1 and titrated every four weeks up to 26 mg, held for the final four weeks of a 28-week course. Mean weight fell 11.6% on dapiglutide versus 0.2% on placebo, which Zealand later described as 11.4% placebo-corrected (Zealand nine-month 2025 report). Zealand’s chief medical officer, David Kendall, said the result “appears on par with the most efficacious once-weekly GLP-1 receptor agonist-based therapy on the market today” (Patient Care, June 2025).

That comparison needs care. Part 2 had only 20 people on the drug, about 93% were men, and median BMI was 28.8, lower than in typical obesity trials. Analysts at William Blair flagged these “atypical patient characteristics” at the time (BioSpace, November 2025). The trial was also not designed to measure inflammation or gut barrier benefits, the feature that was supposed to set dapiglutide apart.

4. What side effects did dapiglutide cause?

Across trials, side effects were gastrointestinal and typical of GLP-1 drugs.

In DREAM, nausea was reported by 56% of participants on each dapiglutide dose versus 38% on placebo, and reduced appetite by 61% versus 33%. Constipation affected 44% on 6 mg, 17% on 4 mg and 11% on placebo. No participant stopped because of a drug-related adverse event, and there were no drug-related serious adverse events. One participant on 6 mg died of a lung tumor that the investigator judged unrelated to the trial (Nielsen et al. 2026).

In Phase 1b Part 1, there were no severe treatment-emergent adverse events and one serious event judged unrelated to the drug. Two participants stopped because of moderate vomiting, and 14.3% developed anti-drug antibodies (Zealand, September 2024). In Part 2, at up to 26 mg, there were no serious or severe treatment-emergent adverse events; most events were mild nausea and vomiting, and two participants discontinued because of adverse events (Patient Care, June 2025).

GLP-2 adds a theoretical question that pure GLP-1 drugs do not raise. Because GLP-2 makes intestinal tissue grow, the US label for the GLP-2 drug teduglutide (Gattex) carries a warning about acceleration of neoplastic growth and recommends colonoscopy after the first year of treatment and at least every five years after that (Gattex prescribing information, 2021). Whether anything similar would matter for a GLP-1/GLP-2 drug used long-term in obesity was never tested, since no dapiglutide trial ran longer than 28 weeks.

5. Why was dapiglutide paused?

Zealand announced the decision with its nine-month results on November 13, 2025: “Development of dapiglutide has been paused as part of active portfolio management, focusing investments on programs with the greatest potential for clinical differentiation and long-term value creation.” The company narrowed its 2025 operating-expense guidance to DKK 2.0–2.3 billion to reflect the pause of a program “previously planned to advance to Phase 2b development in 2025” (Zealand nine-month 2025 report).

Press coverage added context. MarketScreener attributed the decision to the complexity of studies needed to show the anti-inflammatory effects and to an increasingly competitive GLP-1 market; Zealand’s shares rose more than 5% that day (MarketScreener, November 2025). Zealand said it would go “full speed” on its two partnered obesity programs instead (BioSpace, November 2025):

• Petrelintide, an amylin analog co-developed with Roche
• Survodutide, a GLP-1/glucagon dual agonist licensed to Boehringer Ingelheim

In February 2026, a KBC Securities note that lowered its Zealand price target listed “the withdrawal of dapiglutide” as one factor (Tradingsat, February 2026).

Status as of November 8, 2026: Zealand’s own wording is “paused,” not “discontinued,” and no restart, partnership or new trial has been announced. The Phase 1b trial is listed on ClinicalTrials.gov as terminated by sponsor decision, with the note that the last subject’s last visit was completed on March 21, 2025, as planned (NCT06000891). No dapiglutide trial is recruiting.

6. Was the gut-barrier idea ever tested in people?

Not in a way that produced public results. Zealand described DREAM as a trial meant to “gain key mechanistic insights into the effects of dapiglutide on inflammatory markers” over 12 weeks (Zealand nine-month 2025 report). The peer-reviewed DREAM paper reports weight, waist size, body composition, blood pressure, heart rate, glucose and lipid results, and baseline levels of the inflammation marker hs-CRP, but its main findings do not include changes in gut-barrier or inflammation markers (Nielsen et al. 2026). The authors also noted that no effect on circulating lipids was seen.

The barrier evidence that does exist comes from mice with a shortened bowel, where dapiglutide tightened the junctions between intestinal cells in the jejunum but had no barrier effect in the colon (Reiner et al. 2022). Mice after bowel surgery are a very different setting from adults with obesity. That gap between the rationale and the human evidence is part of why proving the GLP-2 benefit would have required the long, complex trials that Zealand chose not to fund.

Program timeline

Sources: NCT03994549; NCT04612517; Zealand, June 2022; Nielsen et al. 2026; Zealand, September 2024; Zealand nine-month 2025 report.

7. How did dapiglutide compare with other weight-loss drugs?

Survodutide’s 76-week SYNCHRONIZE-1 endpoint comes from Zealand’s own report (Zealand nine-month 2025 report). No head-to-head trial was run. The 11.6% at 28 weeks came from a tiny, mostly male group, so it cannot be compared fairly with large Phase 3 results for semaglutide or tirzepatide. The real question for dapiglutide was never whether GLP-1 activity causes weight loss, which is well established, but whether adding GLP-2 offered something extra. That question went unanswered.

8. What does dapiglutide mean for people on GLP-1 therapy?

There is no dapiglutide to switch to. It was never approved and is not being developed. Anyone offered “dapiglutide” from a peptide vendor is being sold an unverified product.

The GLP-2 idea is still alive elsewhere. GLP-2 drugs remain in use and development for short bowel syndrome, and the concept of combining gut-barrier effects with weight loss may reappear in other molecules. For now, there is no human evidence that adding GLP-2 improves outcomes for people with obesity.

Side effects would have overlapped fully. Nausea, reduced appetite, constipation and vomiting were the leading events, the same profile people know from semaglutide and tirzepatide. Combining dapiglutide with another GLP-1 drug was never studied and would have doubled up on the same mechanism.

Body composition data are thin. DREAM measured fat and fat-free mass by bioelectrical impedance, a less precise method than DXA, and found no significant differences from placebo over 12 weeks (Nielsen et al. 2026). The broader evidence on GLP-1 drugs and muscle loss is the better guide.

Its half-life matched other weekly drugs. At roughly five days, it would have cleared over several weeks after a last dose, like semaglutide. The guide to how long a GLP-1 stays in your system explains the general arithmetic.

9. Dapiglutide FAQ

• Is dapiglutide still in development?

  No active development has been announced since November 13, 2025, when Zealand Pharma said development had been paused as part of portfolio management. Zealand had planned a Phase 2b trial in 2025, which did not go ahead. A February 2026 analyst note described the program as withdrawn from Zealand's valuation. As of November 8, 2026, no restart or licensing deal has been announced.

• How much weight loss did dapiglutide cause?

  It depended heavily on dose. At 4 and 6 mg for 12 weeks, the DREAM trial found no statistically significant difference from placebo. At doses titrated up to 13 mg for 13 weeks, placebo-corrected loss was up to 8.3%. At doses titrated to 26 mg for 28 weeks, mean weight loss was 11.6% versus 0.2% on placebo, in a small group of 30 that was about 93% male.

• What does GLP-2 do?

  GLP-2 is a gut hormone released alongside GLP-1. It makes the lining of the small intestine grow and absorb better, which is why GLP-2 drugs such as teduglutide treat short bowel syndrome. Zealand hoped GLP-2 activity would strengthen the gut barrier and reduce the low-grade inflammation linked to obesity. That benefit was never shown in people with obesity.

• Is dapiglutide the same as a GLP-2 drug like teduglutide?

  No. Teduglutide is a pure GLP-2 agonist for short bowel syndrome. Dapiglutide activates both GLP-1 and GLP-2 receptors, with a stronger GLP-1 effect, and was developed for obesity. Early mouse studies did test it in a short bowel model.

• Why did Zealand pause dapiglutide?

  Zealand said it wanted to focus investment on programs with the greatest potential for clinical differentiation. Coverage at the time cited the increasingly crowded GLP-1 market and the long, complex trials that would be needed to prove the anti-inflammatory benefit. Zealand is concentrating on petrelintide, its amylin analog partnered with Roche, and survodutide, partnered with Boehringer Ingelheim.

• Is dapiglutide the same as tirzepatide or a 'GLP-2' drug people talk about online?

  No. People sometimes call tirzepatide a 'GLP-2' because it is a dual agonist, but tirzepatide targets GLP-1 and GIP. Dapiglutide is one of the few drugs that actually acts on the GLP-2 receptor.

• Can I buy dapiglutide?

  No legitimate product exists. Dapiglutide was only ever available inside clinical trials, and development is paused. Anything sold online under that name is unregulated and of unknown content.

10. Sources